Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Will Santa bring Sorrento investors news before Christmas? I don't know but I do know there is a lot of news coming in Q1 of the New Year!
FIVE (5) REASONS SORRENTO SHAREPRICE COULD RISE IN EARLY 2022!
1. ABIVERTINIB $61 Billion global market partnership(s). There will be multi-billion upfront, milestone and royalty payments. And look to the partnership partners to become the eventual buyout actors!
2. SCILEX SPINOFF. SP-102 fuller data is due next month. This new treatment could gross $6-10 billion annually. The partner is a wealthy Singapore based venture capital firm.
3. COVISTIX REVENUE STREAM. Sales are recording in Q4 of 2021 and will ramp up in Q1 of 2022. Europe, Central and South America, Canada, Japan and the US will follow.
4. COVI-AMG, COVIDROPS, COVI-MSC, SP-102, ABIVERTINIB(cancer and Covid) news is expected in Q1 2022 as are more EUA's. SP-102 and ABIVERTINIB revenue expected in 2H of 2022.
5. ORAL MP18 based PAN-COVID ANTI-VIRAL. A peer-reviewed publication was released showing strong pan-Covid activity (including Omicron). This could enter the clinic in Q1 or Q2. A world-wide development and marketing partner might be expected. Look for something better than Merck or Pfizer's drugs!
Investors say "SHOW US THE MONEY"...and that will happen big time in 2022!
Have a look at the latest updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.

***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing could occur in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus in phase 1b
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library

FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's are producing revenue in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. Giant ABIVERTINIB centered partnership(s) coming soon! And SP-102 sales could begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!